Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing

Executive Summary

Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.

Advertisement

Related Content

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
As Saline Shortages Persist, Providers Pin Hopes On Feds Demanding Backup Manufacturing Capacity
Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
J.P. Morgan Notebook Day 2: Walmsley On Diversity, Amgen's Overseas Cash, Growing Opdivo, Mylan On US Generic Pricing, Boston's Pipeline And J&J In Alzheimer's
Drug Price Hikes, Shortages Follow FDA Crackdown On Unapproved Drugs
FDA's Gottlieb Looks To Resuscitate Competition For Shortage Drugs
Generic Manufacturers Try To Up Their Game As US Pressure Persists

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel